Heron Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HRTX research report →
Companywww.herontx.com
Heron Therapeutics, Inc. , a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
- CEO
- Craig Alexander Collard
- IPO
- 1987
- Employees
- 122
- HQ
- Cary, CA, US
Price Chart
Valuation
- Market Cap
- $133.48M
- P/E
- -5.18
- P/S
- 0.89
- P/B
- 17.54
- EV/EBITDA
- -12.11
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 71.12%
- Op Margin
- -6.94%
- Net Margin
- -20.53%
- ROE
- -1115.29%
- ROIC
- -6.72%
Growth & Income
- Revenue
- $154.90M · 7.36%
- Net Income
- $-20,195,000 · -48.71%
- EPS
- $-0.12 · -34.68%
- Op Income
- $-2,538,000
- FCF YoY
- -15.16%
Performance & Tape
- 52W High
- $2.30
- 52W Low
- $0.74
- 50D MA
- $0.96
- 200D MA
- $1.20
- Beta
- 1.71
- Avg Volume
- 2.31M
Get TickerSpark's AI analysis on HRTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 6, 26 | Hensley Mark Earl | other | 125,000 |
| May 6, 26 | Hensley Mark Earl | other | 125,000 |
| Apr 30, 26 | Hensley Mark Earl | other | 11,770 |
| Apr 30, 26 | Hensley Mark Earl | other | 11,770 |
| Apr 30, 26 | Forbes William P | other | 11,770 |
| Apr 30, 26 | Forbes William P | other | 11,694 |
| Apr 30, 26 | Forbes William P | other | 11,770 |
| Apr 30, 26 | Forbes William P | other | 11,694 |
| Apr 30, 26 | Duarte Ira | other | 13,535 |
| Apr 30, 26 | Duarte Ira | other | 11,694 |
Our HRTX Coverage
We haven't published any research on HRTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HRTX Report →